Curtis M A, Aduse Opoku J, Rangarajan M, Gallagher A, Sterne J A C, Reid C R, Evans H E A, Samuelsson B
MRC Molecular Pathogenesis Group, Medical Microbiology, Bart's and the London, Queen Mary's School of Medicine and Dentistry, United Kingdom.
Infect Immun. 2002 Dec;70(12):6968-75. doi: 10.1128/IAI.70.12.6968-6975.2002.
The Arg- and Lys-gingipains of Porphyromonas gingivalis are important virulence determinants in periodontal disease and may correspond to targets for immune- or drug-based treatment strategies. In this investigation we aimed to determine which of these enzymes represents the most promising molecular target for protease inhibitor-based therapy and to examine the effectiveness of the resultant compound in a murine virulence assay. Isogenic mutants with mutations in rgpA and rgpB (encoding Arg-gingipains) and in kgp (encoding Lys-gingipain) and a double mutant with mutations in rgpA and rgpB were prepared by using P. gingivalis W50. The virulence of these mutants indicated that Kgp is a promising drug target. Combinatorial chemistry was used to define the optimal substrate of Kgp, and from this information a specific slowly reversible inhibitor with a nanomolar K(i) was designed and synthesized. Growth of P. gingivalis W50 in the presence of this compound resembled the phenotype of the kgp isogenic mutant; in both instances bacterial colonies failed to form pigment on blood agar, and only poor growth was obtained in a defined medium containing albumin as the sole protein source. Furthermore, pretreatment of the wild-type organism with the Kgp inhibitor led to a significant reduction in virulence in the murine assay. These data emphasize the conclusion that Kgp is an important factor for both nutrition and virulence of P. gingivalis and that inhibitors of this enzyme may have therapeutic potential for the control of P. gingivalis infections. Protease inhibitors may be a potentially novel class of antimicrobial agents with relevance to the control of other bacterial pathogens.
牙龈卟啉单胞菌的精氨酸和赖氨酸牙龈蛋白酶是牙周疾病中重要的毒力决定因素,可能是基于免疫或药物治疗策略的靶点。在本研究中,我们旨在确定这些酶中哪一种是基于蛋白酶抑制剂治疗最有前景的分子靶点,并在小鼠毒力试验中检验所得化合物的有效性。利用牙龈卟啉单胞菌W50制备了rgpA和rgpB(编码精氨酸牙龈蛋白酶)以及kgp(编码赖氨酸牙龈蛋白酶)发生突变的同基因突变体,还有rgpA和rgpB均发生突变的双突变体。这些突变体的毒力表明Kgp是一个有前景的药物靶点。采用组合化学方法确定Kgp的最佳底物,并据此设计合成了一种K(i)为纳摩尔级的特异性缓慢可逆抑制剂。在该化合物存在的情况下,牙龈卟啉单胞菌W50的生长类似于kgp同基因突变体的表型;在这两种情况下,细菌菌落在血琼脂上均不能形成色素,并且在以白蛋白作为唯一蛋白质来源的限定培养基中生长很差。此外,用Kgp抑制剂对野生型菌株进行预处理导致在小鼠试验中毒力显著降低。这些数据强调了以下结论:Kgp是牙龈卟啉单胞菌营养和毒力的重要因素,该酶的抑制剂可能具有控制牙龈卟啉单胞菌感染的治疗潜力。蛋白酶抑制剂可能是一类潜在的新型抗菌剂,与控制其他细菌病原体有关。